The United States will target the EU, Switzerland, China, Japan and India, among others, in a Section 301 investigation, which will include scrutiny of the pharmaceutical sector. The focus will be on…
3742
7 months ago
LinkedIn Content Strategy & Writing Style
Unknown
1 person tracking this creator on ViralBrain
This creator positions themselves as a high-level geopolitical trade analyst specializing in the intersection of international policy and the pharmaceutical supply chain. Their content strategy centers on dissecting the granular implications of U.S. trade investigations, shifting the focus from traditional intellectual property debates to the emerging realities of industrial reshoring and retaliatory tariffs. They are notable for their ability to bridge the gap between macro trade law and specific corporate impact, particularly regarding how bilateral trade surpluses influence national security mandates. By blending regulatory foresight with economic diplomacy, they provide a sophisticated perspective on how global pharmaceutical giants must navigate the tension between European manufacturing hubs and aggressive American protectionism.
0
The United States will target the EU, Switzerland, China, Japan and India, among others, in a Section 301 investigation, which will include scrutiny of the pharmaceutical sector. The focus will be on…
MFN deal number 17 offers a brand new gene therapy free of charge in the United States. Regeneron—the last of the 17 companies that received a letter from President Trump in July 2025 to reach an agre…
France’s Haute Autorité de Santé (HAS; National Health Authority) has taken the unusual step of writing an open letter to a business newspaper, Les Echos, “defending scientific independence in the fac…
Do the paintings of Edvard Munch offer a suitable depiction of where we stand with MFN? I made this suggestion at the start of a presentation I delivered in Oslo this week. I was speaking at the ann…
The competitiveness of the European pharmaceutical sector in the face of immediate pressure from US policy and growing competition from China: that was the subject of an interview I gave to Dagens Med…
Not to be missed: truly thought-provoking comments on MFN from the Spanish Health Secretary, Javier Padilla in his Substack. He starts with the question: “Could price transparency for medicines mean…
Free tools to help you write, score, and benchmark in the same style.
Other creators worth studying alongside Unknown.
ViralBrain plans, writes, and schedules your LinkedIn content, using official LinkedIn APIs so your account stays safe.
Write like Unknown.
